SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.

Shanghai Shyndec Pharmaceutical Co., Ltd.

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-05-13			5-day change	1st Jan Change
9.460 ^CNY	-0.94%		-1.77%	-6.34%

Apr. 29	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 13	Shanghai Shyndec Pharmaceutical Expects Up to 65% Decline in Q1 Attributable Profit; Shares Slide 6%	MT

Shanghai Shyndec Pharmaceutical Passes Drug Evaluation for Calcium Gluconate Injection

Published on 11/27/2024 at 01:45 am EST - Modified on 11/27/2024 at 01:46 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shanghai Shyndec Pharmaceutical Co., Ltd.

Apr. 29	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 13	Shanghai Shyndec Pharmaceutical Expects Up to 65% Decline in Q1 Attributable Profit; Shares Slide 6%	MT
Apr. 07	Shanghai Shyndec Pharmaceutical Gets China Supplementary Drug Approval for Expectorant	MT
Apr. 07	Shanghai Shyndec Pharmaceutical Gets Regulatory Approval for Kidney Drug	MT
Mar. 27	Shanghai Shyndec pharmaceutical 2025 net profit down 13.1% Y/Y	RE
Mar. 25	Shanghai Shyndec Pharmaceutical Acquires Muscle Relaxant Market Authorization for 10.5 Million Yuan	MT
Feb. 25	Shyndec Pharmaceutical Gets China Approval for Antidepressant	MT
Feb. 12	Shyndec Pharmaceutical Secures Bids For 51 Drugs in China's Latest Procurement Program	MT
Feb. 09	Shyndec Pharmaceutical's Subsidiary Passes GMP Inspection	MT
Jan. 27	Shanghai Shyndec Pharmaceutical's Attributable Profit Slides 13%	MT
Jan. 26	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Jan. 13	Shyndec Pharmaceutical's Generic Drug Secures Approval for Antibiotic Consistency Evaluation	MT
Dec. 26	Shyndec Pharmaceutical Gets China Nod for Antipsychotic	MT
Dec. 12	Shyndec Pharma Gets Regulatory Approval for Cardiovascular Drug	MT
Dec. 01	Shanghai Shyndec Pharmaceutical Gets Registration for Opioid Analgesic	MT

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

Duration

Period

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

600420: Dynamic Chart

SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

Employees

9,697

Sector

Pharmaceuticals

More about the company